HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART

Table 2

Studies of high-dose chemotherapy with autologous stem cell transplantation in relapsed HIV-associated lymphomas.

Study	𝑁	%HL	cART	Complete response	Disease-free survival	Overall survival	Treatment-related mortality
Gabarre et al. [38]	14	43%	Yes	71%	29% (26 m)	36% (32 m)	0%
Krishnan et al. [39]	20	10%	Yes	90%	85% (32 m)	85% (32 m)	5%
Serrano et al. [40]	14	21%	Yes	73%	65% (30 m)	65% (30 m)	0%
Spitzer et al. [41]	20	25%	Yes	53%	49% (6 m)	74% (6 m)	5%
Balsalobre et al. [42]	68	26%	Yes	NR	56% (32 m)	61% (32 m)	4%
Re et al. [43]	50; (27*)	38%	Yes	48% (89%*)	49% (44 m); (74% (44 m)*)	50% (44 m); (75% (44 m)*)	0%
Díez-Martín et al. [44]	53	34%	Yes	NR	61% (30 m)	62% (30 m)	NR

NR: not reported.
*Indicates results for only patients who received high-dose chemotherapy followed by autologous stem cell transplantation.